trending Market Intelligence /marketintelligence/en/news-insights/trending/Bi_RZyFzzi7g_LaVzq_pSw2 content esgSubNav
In This List

Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Pfizer, eFFECTOR enter licensing, collaboration deal to develop cancer therapies

Pfizer Inc. has joined with San Diego-based private biotech eFFECTOR Therapeutics Inc. to develop small-molecule inhibitors of a certain protein that is activated in a number of human cancers.

The collaboration will focus on the development of small-molecule inhibitors of eukaryotic initiation factor 4E, a protein that resists certain cancer treatments and is linked to poor prediction of the disease.

Under the exclusive worldwide license and collaboration agreement, Pfizer will pay eFFECTOR $15 million upfront and up to an additional $492 million in potential development and sales milestone payments.

Additionally, eFFECTOR will receive royalties on sales of any products from the program that reaches the commercialization stage.